LZ-CD23 chimera for inhibition of IgE-mediated allergic disease

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Glycoprotein – e.g. – mucins – proteoglycans – etc.

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07K 14735

Patent

active

059657120

ABSTRACT:
CD23 is a low affinity receptor for IgE. The extracellular part of this molecule has been linked to a modified leucine zipper. This results in a trimeric configuration, since the stalk region of the CD23 molecule is itself a weak leucine zipper. This chimeric protein, designated LZ-CD23, interacts with IgE in a much stronger fashion than either simply the extracellular domain alone or the intact membrane CD23. This is the result of an increased avidity due to the stable trimeric configuration. The chimera has approximately at 10,000 fold increased ability to block IgE binding to mast cell/basophils, compared to native soluble CD23. At approximately equal concentrations to added IgE, 80% inhibition of IgE binding to Fc.di-elect cons.RI on mast cells was obtained. Thus, the LZ-CD23 chimera provides a new means for blocking and binding which provides benefits in the treatment of IgE-mediated asthma and allergic diseases.

REFERENCES:
patent: 5554523 (1996-09-01), Reddy
Beavil, A.J., Alpha-helical coiled-coil stalks in the low-affinity receptor for IgE (FcepsilonRII/CD23) and related C-type lectins. Proc. Natl. Acad. Sci. USA. 89:753-757, Jan. l992.
Klein, N.J. II-4 regulates the morphology, cytoskeleton, and proliferation of human umbilical vein endothelial cells: relationship between vimentin and CD23. Internatl. Immunol. 5(3):293-301, 1993.
Sakuma, H., et al., Molecular cloning and functional expression of a cDNA encoding a new member of mixed lineage kinase from human brain. Jour. Biol. Chem. 272(45):28622-28629, Nov. 1997.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

LZ-CD23 chimera for inhibition of IgE-mediated allergic disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with LZ-CD23 chimera for inhibition of IgE-mediated allergic disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LZ-CD23 chimera for inhibition of IgE-mediated allergic disease will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-653912

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.